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Objective. To assess a generic measure of health-related quality of life (HRQOL) as an outcome measure in granuloma-
tosis with polyangiitis (Wegener’s) (GPA).
Methods. Subjects were participants in the Wegener’s Granulomatosis Etanercept Trial (WGET) or the Vasculitis Clinical
Research Consortium Longitudinal Study (VCRC-LS). HRQOL was assessed with the Short Form 36 (SF-36) health survey
that includes physical and mental component summary scores (PCS andMCS, respectively). Disease activity was assessed
with the Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis (BVAS/WG).
Results. The data from 180 subjects in the WGET (median followup 2.3 years, mean number of visits 10) and 237 subjects
in the VCRC-LS (median followup 2.0 years, mean number of visits 8) were analyzed. A 1 unit increase in the BVAS/WG
corresponded to a 1.15 unit (95% conﬁdence interval [95% CI] 1.02, 1.29) decrease for the PCS and a 0.93 (95% CI 0.78,
1.07) decrease for the MCS in the WGET, and to a 1.16 unit decrease for the PCS (95% CI 0.94, 1.39) and a 0.79 unit
decrease for the MCS (95% CI 0.51, 1.39) in the VCRC-LS. In both arms of the WGET study, SF-36 measures improved
rapidly during the ﬁrst 6 weeks of treatment followed by gradual improvement among patients achieving sustained
remission (0.5 improvement in PCS per 3 months), but worsened slightly (0.03 decrease in PCS every 3 months) among
patients not achieving sustained remission (P  0.005).
Conclusion. HRQOL, as measured by the SF-36, is reduced among patients with GPA. SF-36 measures are modestly
associated with other disease outcomes and discriminate between disease states of importance in GPA.
INTRODUCTION
Granulomatosis with polyangiitis (Wegener’s) (GPA) is an
organ- and life-threatening multisystemic disease usually
treated initially with high-dose glucocorticoids in combi-
nation with an additional immunosuppressive drug. For
patients with GPA, the cumulative burden of disease and
treatment-related adverse effects can be substantial (1,2).
In randomized clinical trials (RCTs) of GPA and the
closely related form of vasculitis, microscopic polyangiitis
(MPA), treatment efﬁcacy of experimental agents has al-
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most exclusively been determined by physician-based
measures of disease activity (3–7). These outcome mea-
surement tools were developed by consensus expert opin-
ion panels and then validated for use in trials (8–11).
Patients rank the relative importance of disease manifes-
tations of vasculitis differently than do physicians (1,12),
and patient-reported outcomes might capture elements of
treatment response that are missed by currently used ac-
tivity measures. In a study of other rheumatic diseases,
there is an increased awareness that outcomes such as
fatigue (13) and health-related quality of life (HRQOL) (14)
can discriminate between disease states of importance and
are useful as outcome measures for clinical trials. Several
observational studies have found that patients with sys-
temic vasculitis have reduced HRQOL (15–20). Use of
instruments directly originating from patients as outcome
measures in clinical trials of vasculitis is essential to un-
derstanding how different treatments impact the disease
from the patients’ perspective.
The objective of this study was to explore whether
HRQOL, as measured by the Short Form 36 (SF-36) health
survey, has an additive role as an outcome measure tool
for use in RCTs in GPA beyond currently used outcome
measures; speciﬁcally, 1) describing SF-36 scores among
patients with GPA, 2) exploring the association of SF-36
scores with physician-based and other patient-based out-
come measures, and 3) determining whether SF-36 scores
discriminate between disease states of importance in GPA.
This study is part of a larger effort to develop valid out-
come measures for use in clinical trials of vasculitis
(11,21).
SUBJECTS AND METHODS
Study subjects. Study subjects were participants in the
Wegener’s Granulomatosis Etanercept Trial (WGET) (22,23)
or they were subjects with GPA enrolled in the Vasculitis
Clinical Research Consortium (VCRC) Longitudinal Study
(LS) of GPA. The WGET was a randomized, double-blind
placebo-controlled trial of standard therapy with the ad-
dition of etanercept or placebo for patients with GPA con-
ducted at 8 clinical centers in North America. Subjects
were enrolled at a time of active vasculitis and had study
visits at baseline, 6 weeks, and every 3 months thereafter.
The VCRC-LS is an ongoing longitudinal observational
cohort, where subjects are followed on either annual or
quarterly schedules. Data from all subjects from the WGET
and those subjects with GPA in the VCRC-LS that came for
at least 3 study visits were included in this analysis.
Outcome measures. HRQOL was assessed with the
SF-36 at all study visits in the VCRC-LS observational
cohort and at every other visit in the WGET. In both
cohorts, this information was collected on paper in the
presence of a study administrator who provided no coach-
ing or suggestions regarding the content of the question-
naire. The SF-36 contains 36 items that assess HRQOL in 8
health dimensions: physical functioning, role physical,
bodily pain, general health, vitality, social functioning,
role emotional, and mental health (24,25). Scores for each
dimension/subscale range from 0–100, with higher scores
indicating better HRQOL. Two summary scores are de-
rived from the 8 subscales: the physical component sum-
mary (PCS) score and the mental component summary
(MCS) score, both of which are norm-based scores stan-
dardized to the US general population and transformed to
have a mean of 50 and SD of 10 in the referent population.
Disease activity was assessed with the Birmingham Vas-
culitis Activity Score for Wegener’s Granulomatosis
(BVAS/WG) (10) that measures activity in 34 items cate-
gorized into 9 groups. The BVAS/WG takes values from
0–63, with higher scores representing more manifesta-
tions of active disease. Active disease is deﬁned as a
BVAS/WG of 0 and inactive disease as BVAS/WG  0.
Sustained remission was deﬁned as BVAS/WG  0 lasting
for 6 months.
Disease damage was assessed with the Vasculitis Dam-
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Signiﬁcance & Innovations
● Health-related quality of life, as measured by the
Short Form 36 (SF-36) health survey, is reduced
among patients with granulomatosis with polyan-
giitis (Wegener’s) (GPA), and should be assessed in
clinical trials of vasculitis.
● SF-36 measurements help discriminate among dis-
ease states of importance in GPA.
● These data demonstrate the usefulness of includ-
ing SF-36 as an outcome measure for clinical trials
of GPA.
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age Index (VDI) (9), a 64-item catalog of damage with all
items equally weighted and with scores ranging from
0–64, where higher scores indicate more disease-related
damage. The VDI was measured at baseline and every 6
months thereafter in both the WGET and the VCRC-LS.
Patient-reported disease severity was assessed on a vi-
sual analog scale of 0–100 in theWGET and on an 11-point
scale (0–10) in the VCRC-LS cohort, where the data were
transformed to a scale of 0–100 to allow for comparable
data for both cohorts.
Statistical analysis. The distribution of baseline factors
is described with means and SDs for normally-distributed
variables and medians and interquartile ranges (IQR) for
non–normally distributed variables. For both WGET and
VCRC data, the association of SF-36 summary scores (de-
pendent variables) with other outcome measures (inde-
pendent variables) was explored with mixed linear models
with a random intercept to account for within-individual
correlation of outcomes. Bivariate association between tra-
ditional outcome measures with SF-36 summary scores
was the primary analysis, followed by multivariable ana-
lysis exploring the association of traditionally used out-
come measures with the SF-36 summary scores adjusted
for other outcome measures. The proportion in variability
of the SF-36 measures that was explained by other out-
come measures was estimated by the relative reduction in
the residual variance by comparing the residual variance
of the model that included BVAS/WG, VDI, patient-re-
ported severity, and the random effect for each subject
with the residual variance of a model that only included
the random effect for each patient (intercept only model).
Analyses were done separately for each cohort.
For subjects in the WGET only, the longitudinal trajec-
tory of mean summary SF-36 scores was assessed with a
mixed linear model with a random intercept to account for
the within-individual correlation of the SF-36 measures
and linear splines to allow for different rate of change in
HRQOL with time. After visual inspection of data, a knot
was placed at the time of 6 weeks of followup.
To determine if the SF-36 longitudinal trajectories are
associated with sustained remission beyond what would
be due to their association with disease activity, a
simulation-based analysis was used. For this analysis, the
null hypothesis was that there is no further association
between the SF-36 measures and sustained remission than
that which is induced by their association with the BVAS/
WG. To test this hypothesis, the mean difference between
subjects with sustained remission and those without in the
PCS and MCS over time in the WGET were compared to a
95% conﬁdence band for the expected difference in these
changes over time under the null hypothesis. If the ob-
served data went outside these conﬁdence bands, that
would indicate that the null hypothesis should be rejected
at the 0.05 signiﬁcance level.
Simulations were used to create the 95% conﬁdence
bands under the null hypothesis. In the simulations, ran-
dom number generators were used to create values for the
PCS and MCS at all time points in 200 artiﬁcial data sets
that mimic the WGET data but that also follow the null
hypothesis. These artiﬁcial data sets mimic the WGET in
the following ways: 1) the same numbers of subjects, 2) the
same BVAS/WG scores, 3) the same linear association
between the BVAS/WG and PCS and MCS, and 4) the same
PCS and MCS means, SDs, and within-subject correla-
tions. Differences in the mean trajectories in subjects that
achieved sustained remission and those that did not
achieve sustained remission were calculated for each data
set at each time. The lower 2.5 percentile and upper 97.5
percentile of these differences were used to create the 95%
conﬁdence band. All statistical analyses were done using
SAS software, version 9.1.
RESULTS
Baseline characteristics. Data from 180 subjects in the
WGET and 228 subjects in the VCRC-LS cohort were used
for analysis. Baseline demographic and disease character-
istics are summarized in Table 1. Baseline visit SF-36
scores were reduced from those expected in the general
population, and more so in the WGET cohort where all
subjects had active disease at baseline (Table 2).
Association of SF-36 summary scores with other vas-
culitis outcome measures. In both study cohorts, the
SF-36 summary measures were inversely associated with
disease activity, i.e., a 1-unit increase in the BVAS/WG
Table 1. Baseline characteristics in the 2 study cohorts*
WGET
(n  180)
VCRC-LS
(n  228)
Age, mean  SD years 49.9  15.4 49.1  16.7
Women, % 40.0 52.6
Disease duration, median (IQR) years 0.4 (0.1–2.9) 4.0 (1.9–8.4)
Followup, median (IQR) years 2.3 (1.3–2.8) 2.3 (1.9–2.9)
No. of visits, median (IQR) 10 (7–13) 7 (4–10)
BVAS/WG at baseline, median (IQR) (range) 6 (4–9) (2–18) 0 (0–1) (0–9)
VDI at baseline, mean  SD 1.8  1.9 2.2  2.1
* WGET Wegener’s Granulomatosis Etanercept Trial; VCRC-LS  Vasculitis Clinical Research Consor-
tium Longitudinal Study; IQR  interquartile range; BVAS/WG  Birmingham Vasculitis Disease Activ-
ity Score for Wegener’s Granulomatosis; VDI  Vasculitis Damage Index.
HRQOL as an Outcome Measure in GPA 275
corresponded to a decrease in PCS by 1.15 (95% conﬁ-
dence interval [95% CI] 1.02, 1.29) in the WGET and by
1.06 (95% CI 0.82, 1.31) in the VCRC-LS. A 1-unit increase
in BVAS/WG corresponded to a decrease in MCS by 0.93
(95% CI 0.78, 1.07) in the WGET and by 0.89 (95% CI 0.58,
1.20) in the VCRC-LS. In both study cohorts, SF-36 sum-
mary measures were inversely associated with patient-
reported disease severity (Table 3). In the bivariate analy-
sis, the VDI was signiﬁcantly associated with PCS in the
VCRC-LS only (Table 3) and not associated with MCS in
either cohort. However, in an analysis adjusted for disease
activity (BVAS/WG), there was a statistically signiﬁcant
association between damage and PCS in the WGET, with a
1-unit increase in VDI corresponding to a decrease in PCS
by 0.91 (95% CI 0.44, 1.38). In the WGET, the BVAS/WG,
the VDI, and patient-reported disease severity together
explained 23% and 15% of the variance in PCS and MCS,
respectively. In the VCRC-LS, these 3 outcome measures
together explained 16% and 5% of the variance in PCS and
MCS, respectively (Table 3).
Longitudinal changes in SF-36 summary measures. In
the WGET cohort, where all subjects had active disease at
baseline, 126 out of 180 subjects (70%) achieved sustained
remission. The SF-36 summary scores improved rapidly
during the ﬁrst 6 weeks for all patients. However, after 6
weeks there was more gradual improvement (0.5 in PCS
per each 3-month interval) among those who achieved
sustained remission versus a slight worsening (0.03 in
PCS) among those who did not achieve sustained remis-
sion (P  0.005 for the difference between those that
achieved sustained remission and those who did not
achieve sustained remission). Results were similar for
MCS, with improvement by 0.4 points per each 3-month
interval among those who achieved sustained remission
versus slight worsening by 0.1 among those who did not
achieve remission (P  0.005 for difference between those
that achieved sustained remission and those who did not
achieve sustained remission) (Figure 1).
Unique contribution of SF-36 summary measures be-
yond measure for disease activity. Figure 2 shows the
observed difference in PCS and MCS over time between
subjects with sustained remission and those without, com-
pared to the expected difference and its 95% CI under the
null hypothesis of there being no association beyond that
induced by the BVAS/WG. The observed data escapes the
conﬁdence limits for both the PCS and MCS, therefore
indicating a rejection of this null hypothesis. For the PCS,
the observed difference escapes the conﬁdence band al-
most immediately, indicating that the null hypothesis and
the observed data are quite discordant. For the MCS, the
observed difference is slower to leave the conﬁdence band
and stays somewhat closer, indicating that the discrepancy
is likely not to be as large.
Table 2. SF-36 measures at baseline*
WGET
(n  180)
VCRC-LS
(n  228)
Physical functioning 55.8  28.1 71.7  25.4
Role physical 16.6  31.6 62.8  31.5
Bodily pain 47.7  28.3 65.4  27.0
General health 46.0  20.2 52.0  22.6
Vitality 35.6  21.6 49.9  23.0
Social functioning 49.5  28.5 69.7  27.9
Role emotional 53.5  44.8 76.0  28.6
Mental health 53.5  44.8 71.2  19.3
PCS 33.5  9.7 43.6  10.3
MCS 44.2  11.6 46.5  11.7
* Short Form 36 (SF-36) health survey measures are the mean SD.
WGET  Wegener’s Granulomatosis Etanercept Trial; VCRC-LS 
Vasculitis Clinical Research Consortium Longitudinal Study; PCS
physical component summary score; MCS  mental component
summary score.
Table 3. Association between SF-36 summary measures and physician-based and
patient-reported disease outcomes*
PCS MCS
WGET
BVAS/WG 1.15 (1.29, 1.02) 0.93 (1.07, 0.78)
VDI 0.28 (0.77, 0.22) 0.16 (0.32, 0.064)
Ptglobal 0.14 (0.15, 0.13) 0.12 (0.13, 0.10)
Variance in SF-36 measures explained
by BVAS/WG, VDI, and Ptglobal, %
23 15
VCRC-LS
BVAS/WG 1.06 (1.31, 0.82) 0.89 (1.20, 0.58)
VDI 0.40 (0.73, 0.07) 0.06 (0.45, 0.33)
Ptglobal 0.14 (0.16, 0.13) 0.11 (0.13, 0.09)
Variance in SF-36 measures explained
by BVAS/WG, VDI, and Ptglobal, %
16 5
* Bivariate association of Short Form 36 (SF-36) health survey measures with other disease outcomes is
expressed with beta-coefﬁcients, which represent the expected change in SF-36 measures (physical
component summary [PCS] and mental component summary [MCS]) per 1 unit increase in other outcome
measures with 95% conﬁdence intervals. WGET  Wegener’s Granulomatosis Etanercept Trial; BVAS/
WG  Birmingham Vasculitis Disease Activity Score for Wegener’s Granulomatosis; VDI  Vasculitis
Damage Index; Ptglobal  patient-reported disease severity; VCRC-LS  Vasculitis Clinical Research
Consortium Longitudinal Study.
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DISCUSSION
The ﬁndings of this study are consistent with previous
reports that HRQOL is reduced among patients with GPA
(15–20) and provide evidence that SF-36 is a valid out-
come measure for use in clinical trials of GPA. HRQOL, as
measured by the SF-36, is especially reduced during peri-
ods of active disease in GPA and rapidly improves with
induction treatment. SF-36 summary scores are associated
with both physician-based measures of disease and pa-
tient-reported disease severity. The SF-36 is a generic tool
for assessing HRQOL and its utility has been validated in
multiple chronic inﬂammatory diseases (26–28). The SF-36
is designed to capture elements of HRQOL across different
diseases and cultural groups. BVAS/WG and VDI only
explain a modest proportion in the variability of the SF-36
measures, and SF-36 measures discriminate between dis-
ease states beyond their association with BVAS/WG.
Outcome measurement tools for determining efﬁcacy of
potential therapeutic agents for GPA and MPA are under
active development by the Outcome Measures in Rheuma-
tology Vasculitis Working Group (11,21). Systemic vascu-
litides are rare diseases, recruitment for clinical trials is
challenging, and compared to most other diseases, clinical
trials of vasculitis involve relatively small sample sizes.
The success of RCTs in providing high-level evidence for
therapeutic approaches in vasculitis is dependent on the
successful design of outcome measures with good discrim-
inatory power between effective and ineffective therapies.
This goal can sometimes be achieved by combining indi-
vidual components that modestly correlate with each
other into a composite measure more sensitive to change
than its individual components (29,30). Our ﬁndings sug-
gest that HRQOL could represent one disease domain con-
tributing to such a composite index in GPA
This study has several important strengths. The data
sources are 2 large, well-deﬁned patient cohorts with GPA,
each followed for more than 2 years. One data source
represents a trial population for which the utility of SF-36
measures were under study, and the other source is an
observational cohort, adding to the generalizability of our
ﬁndings to other patient populations with GPA. The lon-
gitudinal nature of the data provides repeated SF-36 mea-
surements allowing for an evaluation of longitudinal
changes during the disease course. Furthermore, along
with measurements of HRQOL, other established outcome
measures for GPA were obtained, all with standardized
methods, allowing for the exploration of how SF-36 mea-
sures compare with other currently used outcome mea-
sures in GPA.
This study also has some limitations to consider. Dis-
ease activity (and other outcome measures) was measured
with the BVAS/WG at scheduled study visits only. Since
the BVAS/WG reﬂects disease activity during the 28 days
prior to the study visits, periods of disease activity be-
tween could be missed. Furthermore, the VCRC-LS data
might have been subject to a selection bias with differen-
tial followup between those with periods of active disease
and those with inactive disease. It is possible that the
Figure 1. Longitudinal changes in mean Short Form 36 health survey summary scores in the Wegener’s Granulomatosis Etanercept Trial
cohort according to whether or not subjects achieved sustained remission: A, data for physical component summary (PCS) and B, data for
the mental component summary (MCS). Time in years is on the x-axis and mean scores are on the y-axis. Broken lines represent 95%
conﬁdence limits.
Figure 2. A longitudinal change in the difference of true and artiﬁcial summary Short Form 36 (SF-36) health survey measures according
to whether sustained remission was achieved: A, data for physical component summary (PCS) and B, data for the mental component
summary (MCS). Time in years is on the x-axis, and the difference in scores between those who did and did not achieve sustained
remission is on the y-axis. The artiﬁcial scores are presented with 95% conﬁdence limits. There is greater difference in the true SF-36
summary measures than is observed for the artiﬁcial scores.  score  difference in scores between those who did and did not achieve
sustained remission; PCSART  artiﬁcial PCS score; MCSART  artiﬁcial MCS score.
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SF-36 captures effects of nonvasculitic conditions on
HRQOL. However, data on comorbidities were not avail-
able for our analysis. Despite this lack of speciﬁcity, the
SF-36 still serves as an important outcome measure and
could differentiate between active treatment of placebo,
with respect to medication effects that affect HRQOL and
are of importance to patients. Additionally, neither of the
study cohorts are inception cohorts and therefore patients
who present with rapidly fatal initial disease are under-
represented in the current study.
The lack of association between the SF-36 and disease-
related damage is notable and is in contrast to a previous
analysis from the WGET cohort in which a statistically
signiﬁcant correlation was found between PCS (but not
MCS) and VDI (2). The reason for these discrepant ﬁndings
is that the 2005 analysis was cross-sectional with all data
from a single time point (at 1 year of followup), whereas
the current analysis utilizes the longitudinal nature of the
data, using all available study visits up to 2 years from
enrollment of the last subject. The results of the primary
analysis demonstrating no association between disease-
related damage and PCS may represent a spurious ﬁnding,
while the secondary analysis, adjusted for the BVAS/WG,
is more appropriate. While all subjects in the WGET had
active disease at baseline, 44% of the subjects had new
disease at enrollment and could not have accumulated
disease-related damage; these subjects also had an initial
VDI score of 0, creating an inverse association between
disease activity and disease damage. Therefore, the analy-
sis adjusting for disease activity better captures the true
association between disease damage and PCS in the WGET
cohort and is consistent with the ﬁndings in the separate
VCRC-LS cohort.
This study demonstrates that HRQOL in GPA, as mea-
sured by the SF-36, is associated with vasculitis disease
activity and discriminates between disease states of impor-
tance. Therefore, the SF-36 could capture data on a disease
domain not represented by other currently used outcome
measures. The SF-36 should be included in the core set of
outcome measures in GPA (11). Future research on using
the SF-36 in trials of vasculitis should include determina-
tion of minimally clinically important changes in SF-36
scores, how the SF-36 measures discriminate between ef-
fective and ineffective (or less effective) treatments, and
whether the SF-36 could contribute to a composite out-
come measure.
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